We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Hikma Pharmaceuticals plc (PK) | USOTC:HKMPY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 46.50 | 45.58 | 51.57 | 33 | 21:01:20 |
From Apr 2019 to Apr 2024
By Anthony O. Goriainoff
Hikma Pharmaceuticals PLC said Wednesday that it has resumed the launch of its generic version of GlaxoSmithKline PLC's asthma treatment, Advair Diskus, in the U.S.
The FTSE 100 pharmaceutical company said the move followed the Food and Drug Administration's approval of the amendment to its abbreviated new drug application, submitted in January. The change reflected enhanced packaging controls required to meet industry standards adopted since the time of the initial submission.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
April 21, 2021 02:31 ET (06:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Hikma Pharmaceuticals (PK) Chart |
1 Month Hikma Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
